canyon landscape

Allergan 3101-303-002

A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of atogepant for the prevention of chronic migraine (PROGRESS).

The purpose of this study is to look into the safety and tolerability of daily atogepant in the prevention of migraines. Atogepant is designed to block receptors in your head that may be related to migraine pain.

This research study is looking for approximately 750 participants with migraine. There will be a total of 8 study visits over a period of approximately 20 weeks.

Status
Open and enrolling subjects.
Location
Phoenix, Arizona
Total Participants
750
Primary Sponsor
Allergan

The Jan & Tom Lewis Migraine Treatment Program

Learn more about our specialists and treatments